---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-071478"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:48:36.655479+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reprices stock options for executives to $2.84 per share

## Summary
- Board approved reducing exercise price of certain outstanding options to $2.84 per share (closing price on Dec 16, 2023).
- CEO Talat Imran: 936,444 options repriced from $5.44-$19.56; CFO Svai Sanford: 313,558 options from $5.44-$13.21.
- CSO Mir Hashim: 328,374 options repriced from $5.44-$13.21; all options retain original vesting schedules and expiration dates.
- Repricing covers employees, named executive officers, consultants, and non-employee directors; no other terms modified.
- Board determined repricing best for retention and incentivization without cash outlay or additional equity dilution.

## SEC filing metadata
- accession: 0000950170-23-071478
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023071478/0000950170-23-071478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023071478/rani-20231216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-071478
- JSON: https://secwatch.observer/filing/0000950170-23-071478.json
- Plain text: https://secwatch.observer/filing/0000950170-23-071478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.